Therefore, these findings suggest that Sunitinib is a potential combinatorial agent to enhance the efficacy of CTLA‐4 mAb therapy in the treatment of melanoma or NSCLC. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.